Bank Of New York Mellon Corp Acer Therapeutics Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$0.75 - $1.14 $539 - $819	-719 Reduced 6.53%	10,290 $9.5 Million
Q1 2023 May 09, 2023	BUY	$0.67 - $3.05 $7,376 - $33,577	11,009 New	11,009 $8.35 Million
Q4 2022 Feb 14, 2023	BUY	$1.13 - $4.15 $12,440 - $45,687	11,009 New	11,009 $27,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $3.04 $69 - $176	-58 Reduced 0.52%	11,075 $14,000
Q2 2021 Aug 11, 2021	SELL	$2.52 - $3.18 $3,963 - $5,002	-1,573 Reduced 12.38%	11,133 $31,000
Q1 2021 May 13, 2021	SELL	$2.47 - $4.39 $2,519 - $4,477	-1,020 Reduced 7.43%	12,706 $39,000
Q2 2020 Aug 12, 2020	SELL	$1.53 - $4.53 $11,862 - $35,121	-7,753 Reduced 36.1%	13,726 $47,000
Q1 2020 May 06, 2020	BUY	$1.18 - $5.86 $12,650 - $62,825	10,721 Added 99.66%	21,479 $42,000
Q4 2019 Feb 14, 2020	BUY	$2.85 - $4.2 $1,724 - $2,541	605 Added 5.96%	10,758 $43,000
Q3 2019 Nov 07, 2019	SELL	$1.95 - $3.93 $1,210 - $2,440	-621 Reduced 5.76%	10,153 $32,000
Q2 2019 Aug 12, 2019	BUY	$3.45 - $26.86 $37,170 - $289,389	10,774 New	10,774 $42,000

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.